245 related articles for article (PubMed ID: 21044274)
1. Treatment of diabetic retinopathy with anti-VEGF drugs.
Waisbourd M; Goldstein M; Loewenstein A
Acta Ophthalmol; 2011 May; 89(3):203-7. PubMed ID: 21044274
[TBL] [Abstract][Full Text] [Related]
2. A review of clinical trials of anti-VEGF agents for diabetic retinopathy.
Nicholson BP; Schachat AP
Graefes Arch Clin Exp Ophthalmol; 2010 Jul; 248(7):915-30. PubMed ID: 20174816
[TBL] [Abstract][Full Text] [Related]
3. Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular oedema.
Zehetner C; Kirchmair R; Huber S; Kralinger MT; Kieselbach GF
Br J Ophthalmol; 2013 Apr; 97(4):454-9. PubMed ID: 23385630
[TBL] [Abstract][Full Text] [Related]
4. Diabetic macular edema.
Lang GE
Ophthalmologica; 2012; 227 Suppl 1():21-9. PubMed ID: 22517122
[TBL] [Abstract][Full Text] [Related]
5. Anti-VEGF therapy in proliferative diabetic retinopathy.
Abdallah W; Fawzi AA
Int Ophthalmol Clin; 2009; 49(2):95-107. PubMed ID: 19349790
[No Abstract] [Full Text] [Related]
6. Anti-vascular endothelial growth factor agents for diabetic maculopathy.
Salam A; DaCosta J; Sivaprasad S
Br J Ophthalmol; 2010 Jul; 94(7):821-6. PubMed ID: 19556214
[TBL] [Abstract][Full Text] [Related]
7. Anti-VEGF therapeutic approaches for diabetic macular edema.
Khurana RN; Do DV; Nguyen QD
Int Ophthalmol Clin; 2009; 49(2):109-19. PubMed ID: 19349791
[No Abstract] [Full Text] [Related]
8. Comparison of Aflibercept, Bevacizumab, and Ranibizumab for Treatment of Diabetic Macular Edema: Extrapolation of Data to Clinical Practice.
Heier JS; Bressler NM; Avery RL; Bakri SJ; Boyer DS; Brown DM; Dugel PU; Freund KB; Glassman AR; Kim JE; Martin DF; Pollack JS; Regillo CD; Rosenfeld PJ; Schachat AP; Wells JA;
JAMA Ophthalmol; 2016 Jan; 134(1):95-9. PubMed ID: 26512939
[TBL] [Abstract][Full Text] [Related]
9. Evidence for anti-VEGF treatment of diabetic macular edema.
Bandello F; Berchicci L; La Spina C; Battaglia Parodi M; Iacono P
Ophthalmic Res; 2012; 48 Suppl 1():16-20. PubMed ID: 22907145
[TBL] [Abstract][Full Text] [Related]
10. Intravitreal anti-VEGF drugs as adjuvant therapy in diabetic retinopathy surgery.
Montero JA; Ruiz-Moreno JM; Correa ME
Curr Diabetes Rev; 2011 May; 7(3):176-84. PubMed ID: 21438852
[TBL] [Abstract][Full Text] [Related]
11. Antivascular endothelial growth factor in diabetic retinopathy.
Iacono P; Battaglia Parodi M; Bandello F
Dev Ophthalmol; 2010; 46():39-53. PubMed ID: 20703031
[TBL] [Abstract][Full Text] [Related]
12. Comparative effectiveness of anti-VEGF agents for diabetic macular edema.
Ollendorf DA; Colby JA; Pearson SD
Int J Technol Assess Health Care; 2013 Oct; 29(4):392-401. PubMed ID: 24290332
[TBL] [Abstract][Full Text] [Related]
13. Review of anti-VEGF therapy in proliferative diabetic retinopathy.
Jardeleza MS; Miller JW
Semin Ophthalmol; 2009; 24(2):87-92. PubMed ID: 19373692
[TBL] [Abstract][Full Text] [Related]
14. Treatment of proliferative diabetic retinopathy with anti-VEGF agents.
Salam A; Mathew R; Sivaprasad S
Acta Ophthalmol; 2011 Aug; 89(5):405-11. PubMed ID: 21294854
[TBL] [Abstract][Full Text] [Related]
15. Selective and pan-blockade agents in the anti-angiogenic treatment of proliferative diabetic retinopathy: a literature summary.
Giuliari GP; Guel DA; Cortez MA; Cortez RT
Can J Ophthalmol; 2010 Oct; 45(5):501-8. PubMed ID: 20648074
[TBL] [Abstract][Full Text] [Related]
16. Biological, preclinical and clinical characteristics of inhibitors of vascular endothelial growth factors.
Chong V
Ophthalmologica; 2012; 227 Suppl 1():2-10. PubMed ID: 22517120
[TBL] [Abstract][Full Text] [Related]
17. Anti-angiogenesis drugs in diabetic retinopathy.
Jeganathan VS
Curr Pharm Biotechnol; 2011 Mar; 12(3):369-72. PubMed ID: 20939797
[TBL] [Abstract][Full Text] [Related]
18. A comparative debate on the various anti-vascular endothelial growth factor drugs: pegaptanib sodium (Macugen), ranibizumab (Lucentis) and bevacizumab (Avastin).
Nagpal M; Nagpal K; Nagpal PN
Indian J Ophthalmol; 2007; 55(6):437-9. PubMed ID: 17951900
[TBL] [Abstract][Full Text] [Related]
19. Vascular Endothelial Growth Factor and Diabetic Retinal Disease.
Ajlan RS; Silva PS; Sun JK
Semin Ophthalmol; 2016; 31(1-2):40-8. PubMed ID: 26959128
[TBL] [Abstract][Full Text] [Related]
20. Anti-VEGF Molecules for the Management of Diabetic Macular Edema.
Bandello F; Cicinelli MV; Parodi MB
Curr Pharm Des; 2015; 21(32):4731-7. PubMed ID: 26350530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
